EASDAQ: Fighting for a Lost Cause?

Five years after its formation, Easdaq still hasn't given up the fight to become the pan-European market for growth stocks—but it hasn't won the war, either. Despite its laudable aim—to provide growth companies with European-wide exposure, using a single regulatory environment and trading system—the Brussels-based exchange has so far failed to become the Nasdaq of Europe.

Trading volumes remain low. There are just 60 listed companies, and biotechs—with the exception of a handful including Antisoma PLC...